9 May 2016 14:47
Notice of Results
London, UK, 09 May 2016: BTG plc (LSE: BTG), the specialist healthcare company, will announce its preliminary results for the twelve months ended 31 March 2016 on Tuesday 17 May 2016.
For further information, please contact:
BTG/FTI Consulting
Andy Burrows, VP Corporate & Investor Relations | Ben Atwell / Simon Conway |
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605 | +44 (0)20 3727 1000 |
Stuart Hunt, Investor Relations Manager | |
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536 | |
Chris Sampson, Corporate Communications Director | |
+44 20 7575 1595; Mobile: +44 7773 251 178 |
About BTG
BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com.